Liqmeds

Liqmeds is a specialty pharmaceutical company focused on the development and manufacturing of complex liquid oral and injectable medications. The company specializes in reformulating existing solid-dose drugs into liquid formats to address the needs of patients with swallowing difficulties, such as pediatric and geriatric populations. In 2023, Liqmeds was acquired by Amneal Pharmaceuticals, significantly expanding Amneal's portfolio of high-value, differentiated liquid products. Liqmeds operates R&D and manufacturing facilities that support a growing pipeline of ANDAs and value-added medicines. Their expertise lies in overcoming solubility and stability challenges to create patient-friendly dosage forms.